関連する実験動画

Updated: Feb 19, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

ダパグリフロジンは,ファブリー病のCKD患者の治療に用いられる

Yuri Battaglia^1,2, Nicola Vitturi³, Giacomo Marchi⁴

¹Department of Medicine, University of Verona, Verona, Italy.

Kidney international reports

|February 18, 2026

まとめ

ダパグリフロジンなどのナトリウム・グルコースコトランスポーター2 (SGLT2) 阻害剤は,ファブリー病 (FD) の治療において有望であることが示されています. この研究では,ダパグリフロジンは,慢性腎臓病 (CKD) のFD患者のタンパク質尿を減少させ,腎臓機能の低下を遅らせることが判明しました.

科学分野:

ネフロロジーはネフロロジーを用います.
遺伝学遺伝学とは
薬理学薬理学とは

背景:

ナトリウム・グルコースコトランスポーター2 (SGLT2) 阻害剤は,慢性腎臓病 (CKD) のタンパク質尿を減少させ,疾患進行を遅らせることが知られている.
珍しい遺伝疾患であるファブリー病 (FD) にSGLT2阻害剤の作用に関するデータは限られている.
ファブリー病の患者はしばしばアルブミン尿性CKDを発症し,効果的な治療戦略が必要になります.

研究の目的:

ダパグリフロジンの12ヶ月の有効性を評価し,アルバミヌーリア,プロテヌーリアを軽減し,ファブリー病およびアルバミヌーリックCKDの患者で腎機能を維持する.
この特定の患者集団における推定グルメルフィルタレーション率 (eGFR) 低下に対するダパグリフロジンの影響を評価する.

主な方法:

展望的な多センター研究では,FDおよびアルブミヌリックCKDの成人患者が,安定した酵素置換療法 (ERT) またはミガラスタットおよび最大耐容レニン-アニオテンシンシステム阻害剤 (RAS-i) を受けていた.
ダパグリフロジン10mgを投与し,尿中のアルバミン対クレアチニン比率 (UACR),24時間プロテイン尿,eGFRをベースラインおよび12ヶ月で測定しました.
治療効果を評価し,eGFRの変化を比較するために,混合効果モデルを含む統計分析が使用されました.

主要な成果:

12ヶ月後,ダパグリフロジンはUACRを47.6%と24時間プロテイン尿を22.2%大幅に低下させた.
eGFRはダパグリフロジン治療期間中に安定したままであり,治療前に観察された有意な減少とは対照的です.
9人の患者のうち8人は,ダパグリフロジン治療で,毎年のeGFRの傾き ≤3ml/minを達成しました.

結論:

ダパグリフロジンは,FDおよびアルバミヌリックCKDの患者にアルバミヌリアとプロテインウリアの有意な減少を示した.
この研究は,ダパグリフロジンが腎臓の機能を安定させ,この患者群でeGFRの減少を軽減するのに役立つ可能性があるという予備的な証拠を提供します.
これらの発見は,ファブリー病における腎臓疾患の管理におけるSGLT2阻害剤の潜在的な治療的役割を示唆しています.

キーワード:

ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT ERT GFR (高空飛行法) で飛行する.RAS-iは,RAS-iとして使用されています.SGLT2 阻害剤を投与するミガラステータスとはプロテインウリア (proteinuria) とは

さらに関連する動画

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

関連する概念動画

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Chronic Kidney Disease IV: Nursing Management

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...